Personal Investigators

Dr Alain Wagner (Research Director, CNRS) and Dr Guilhem Chaubet (Researcher, CNRS) are coordinators of this project. They are heads of the BioFunctional Chemistry (BFC) group at the University of Strasbourg (UMR7199), where they develop – among other themes of research – new reactions for the bioconjugation of native proteins and novel linker structures to be utilised in Protein-Drug Conjugates (PDC).

Dr Sarah Cianferani (Research Director, CNRS) is the head of the BioOrganic Mass Spectrometry Laboratory (LSMBO; UMR7178), which scientific objective consists in the development of mass spectrometry methods for protein and peptide characterizations. The LSMBO has a long-standing experience in protein and peptide characterization with focus on proteomics, non-covalent complex interactions and bioinformatics and is equiped with state-of-the-art mass spectrometers.

Prof. Vijay Chudasama is the head of the Chudasama research group at University College London. The group has research interests in the development and application of novel methodologies in Chemical Biology and Organic Synthesis, notably reversible and irreversible chemoselective bioconjugation, aerobic hydroacylation and site-selective dual modification of proteins.

Prof. Christopher Scott is Acting Director of the Centre for Cancer Research and Cell Biology at Queen’s University Belfast (QUB). Chris is internationally renowned for his work in development of antibody and nanomedicine-based therapies for the treatment of cancer and other conditions.

Dr Graham Cotton is the Head of Protein Therapeutics at Almac Discovery, which he joined to bring expertise in peptide and protein chemistry. Graham has responsibility for the technical management of Discovery’s Protein Drug Conjugate key research focus within Almac Discovery and was important in the discovery of the peptide clinical candidate, ALM201.

Prof. Floris Van Delft holds the special chair of ‘Bioconjugate Chemistry’ at the University of Wageningen and is Chief Scientific Officer of SynAffix BV, which he founded in 2010. His research activities are dedicated to development of (copper-free) click chemistry and bioconjugation technologies (proteins, glycans, nucleic acids), with a strong focus on antibody-drug conjugates (ADCs).

Prof. Arne Skerra holds the chair of ‘Biological Chemistry’ at the Technical University of Munich. His research group works on the construction of artificial binding proteins and enzymes with novel, tailored functions, in particular for applications in medical and industrial biotechnology.

Prof. Andreas Pahl is the Head of Research and Development of Heidelberg Pharma AG, a biopharmaceutical company focused on oncology. Heidelberg Pharma was the first company to develop the toxin amanitin into cancer therapies and advance the biological mode of action of the toxin as a novel therapeutic principle.

Dr Thomas Fessard is the Chief Executive Officer of SpiroChem AG, a Swiss fine chemicals company he co-founded in 2011. SpiroChem is the world-leading chemical company on the concept of bioisosterism, possessing a unique repertoire of molecular fragments designed to help medicinal chemists by accelerating drug discovery and lead optimization programmes in the Life Science sector.